Katja Conrath

1.0k total citations
23 papers, 718 citations indexed

About

Katja Conrath is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Epidemiology. According to data from OpenAlex, Katja Conrath has authored 23 papers receiving a total of 718 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 6 papers in Molecular Biology and 6 papers in Epidemiology. Recurrent topics in Katja Conrath's work include Cystic Fibrosis Research Advances (16 papers), Neonatal Respiratory Health Research (9 papers) and Advanced biosensing and bioanalysis techniques (5 papers). Katja Conrath is often cited by papers focused on Cystic Fibrosis Research Advances (16 papers), Neonatal Respiratory Health Research (9 papers) and Advanced biosensing and bioanalysis techniques (5 papers). Katja Conrath collaborates with scholars based in Belgium, United States and Netherlands. Katja Conrath's co-authors include Yoshiro Sohma, Tzyh‐Chang Hwang, L Nelles, Martin Andrews, Thierry Christophe, Christel Menet, Jean H.M. Feyen, Steve De Vos, Ellen M. van der Aar and N. Vandeghinste and has published in prestigious journals such as Journal of Biological Chemistry, The Journal of Immunology and Journal of Medicinal Chemistry.

In The Last Decade

Katja Conrath

23 papers receiving 710 citations

Peers

Countries citing papers authored by Katja Conrath

Since Specialization

Citations

This map shows the geographic impact of Katja Conrath's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katja Conrath with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katja Conrath more than expected).

Fields of papers citing papers by Katja Conrath

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katja Conrath. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katja Conrath. The network helps show where Katja Conrath may publish in the future.

Co-authorship network of co-authors of Katja Conrath

This figure shows the co-authorship network connecting the top 25 collaborators of Katja Conrath. A scholar is included among the top collaborators of Katja Conrath based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katja Conrath. Katja Conrath is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Discovery of GLPG2451, a Novel Once Daily Potentiator for the Treatment of Cystic Fibrosis 2021 ·Journal of Medicinal Chemistry ·(unknown), (unknown), (unknown), Christel Menet, (unknown), (unknown), Caroline Joannesse, (unknown), (unknown), Marlon Cowart, (unknown), (unknown), Maarten Gees, (unknown), Katja Conrath, Martin Andrews	17
2	Novel Correctors and Potentiators Enhance Translational Readthrough in CFTR Nonsense Mutations 2021 ·American Journal of Respiratory Cell and Molecular Biology ·Venkateshwar Mutyam, Jyoti Sharma, Yao Li, Ning Peng, Jianguo Chen, Li Tang, Emily Falk Libby, Ashvani K. Singh, Katja Conrath, Steven M. Rowe	13
3	CFTR Rescue in Intestinal Organoids with GLPG/ABBV-2737, ABBV/GLPG-2222 and ABBV/GLPG-2451 Triple Therapy 2021 ·Frontiers in Molecular Biosciences ·Eyleen de Poel, Sacha Spelier, (unknown), (unknown), Sylvia F. Boj, Katja Conrath, Cornelis K. van der Ent, Jeffrey M. Beekman	5
4	Evaluation of a novel CFTR potentiator in COPD ferrets with acquired CFTR dysfunction 2021 ·European Respiratory Journal ·Niroop Kaza, Vivian Lin, (unknown), Shah S. Hussain, Emily Falk Libby, Harrison Kim, Monica Borgonovi, Katja Conrath, Venkateshwar Mutyam, (unknown), Li Tang, (unknown), (unknown), Trenton R. Schoeb, Hui Min Leung, Guillermo J. Tearney, S. Vamsee Raju, Steven M. Rowe	17
5	Identifying the molecular target sites for CFTR potentiators GLPG1837 and VX-770 2019 ·The Journal of General Physiology ·(unknown), Liming Qiu, Yoshiro Sohma, Katja Conrath, Xiaoqin Zou, Tzyh‐Chang Hwang	56
6	GLPG2737 in lumacaftor/ivacaftor-treated CF subjects homozygous for the F508del mutation: A randomized phase 2A trial (PELICAN) 2019 ·Journal of Cystic Fibrosis ·Silke van Koningsbruggen‐Rietschel, Katja Conrath, Rainald Fischer, Sivagurunathan Sutharsan, (unknown), Wolfgang Gleiber, C. Schwarz, Andreas Hector, Nancy Van Osselaer, Arian Pano, Sam Corveleyn, (unknown), Eva Santermans, (unknown), (unknown), (unknown)	10
7	CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials 2019 ·Journal of Cystic Fibrosis ·Scott C. Bell, Peter J. Barry, K. De Boeck, Pavel Dřevı́nek, J.S. Elborn, Barry J. Plant, (unknown), Eva Van Braeckel, Stijn Verhulst, (unknown), (unknown), (unknown), Herman de Kock, David E. Geller, Katja Conrath, (unknown), Cornelis K. van der Ent	36
8	GLPG1837, a CFTR potentiator, in p.Gly551Asp (G551D)-CF patients: An open-label, single-arm, phase 2a study (SAPHIRA1) 2019 ·Journal of Cystic Fibrosis ·Jane C. Davies, (unknown), Silke van Koningsbruggen‐Rietschel, Pavel Dřevı́nek, Nico Derichs, Edward F. McKone, (unknown), (unknown), Florence Namour, Herman de Kock, Katja Conrath	22
9	Identification of GLPG/ABBV-2737, a Novel Class of Corrector, Which Exerts Functional Synergy With Other CFTR Modulators 2019 ·Frontiers in Pharmacology ·Gert De Wilde, Maarten Gees, (unknown), (unknown), (unknown), (unknown), Ashvani K. Singh, Tzyh‐Chang Hwang, Thierry Christophe, (unknown), (unknown), Nicolas Desroy, Marlon Cowart, Pieter F. W. Stouten, L Nelles, Katja Conrath	27
10	Biological Characterization of F508delCFTR Protein Processing by the CFTR Corrector ABBV-2222/GLPG2222 2019 ·Journal of Pharmacology and Experimental Therapeutics ·Ashvani K. Singh, Yihong Fan, Corina Balut, (unknown), Arlene M. Manelli, Andrew M. Swensen, Ying Jia, Torben R. Neelands, Timothy A. Vortherms, Bo Liu, (unknown), Xueqing Wang, Wenqing Gao, Tzyh‐Chang Hwang, (unknown), Douglas Cyr, Philip R. Kym, Katja Conrath, Chris Tse	22
11	GLPG2222 in CF subjects homozygous for F508DEL : results from a phase II study (FLAMINGO) 2018 ·Ghent University Academic Bibliography (Ghent University) ·(unknown), Predrag Minić, Stijn Verhulst, Eva Van Braeckel, Patrick A. Flume, Steven R. Boas, David H. Geller, Herman de Kock, (unknown), Kai-Christian Müller, (unknown), Katja Conrath, (unknown)	1
12	EPS3.05 GLPG2222 in subjects with cystic fibrosis homozygous for F508del: results from a phase II study (FLAMINGO) 2018 ·Journal of Cystic Fibrosis ·(unknown), (unknown), Stijn Verhulst, Eva Van Braeckel, Patrick A. Flume, Steven R. Boas, David E. Geller, Herman de Kock, (unknown), (unknown), (unknown), Katja Conrath, (unknown)	2
13	Identification and Characterization of Novel CFTR Potentiators 2018 ·Frontiers in Pharmacology ·Maarten Gees, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Pieter F. W. Stouten, Andrew M. Swensen, (unknown), Jan van der Schueren, L Nelles, Martin Andrews, Katja Conrath	33
14	Discovery ofN-(3-Carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-lH-pyrazole-5-carboxamide (GLPG1837), a Novel Potentiator Which Can Open Class III Mutant Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Channels to a High Extent 2017 ·Journal of Medicinal Chemistry ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Caroline Joannesse, (unknown), (unknown), Thierry Christophe, Ellen van der Aar, Monica Borgonovi, L Nelles, Maarten Gees, Pieter F. W. Stouten, Jan van der Schueren, (unknown), Katja Conrath, Martin Andrews	44
15	A common mechanism for CFTR potentiators 2017 ·The Journal of General Physiology ·(unknown), Yoshiro Sohma, Katja Conrath, Tzyh‐Chang Hwang	45
16	WS13.6 GLPG1837 in subjects with cystic fibrosis (CF) and the G551D mutation: results from a phase II study (SAPHIRA1) 2017 ·Journal of Cystic Fibrosis ·Jane C. Davies, (unknown), Silke van Koningsbruggen‐Rietschel, (unknown), Gordon MacGregor, Pavel Dřevı́nek, Katja Conrath, Herman de Kock, (unknown), (unknown), (unknown)	4
17	Identification of a Series of Compounds with Potent Antiviral Activity for the Treatment of Enterovirus Infections 2013 ·ACS Medicinal Chemistry Letters ·Angus M. MacLeod, (unknown), Nicholas J. Palmer, (unknown), Katja Conrath, Martin Andrews, Pieter Leyssen, Johan Neyts	34
18	Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases 2013 ·The Journal of Immunology ·Luc Van Rompaey, René Galien, Ellen M. van der Aar, Philippe Clément-Lacroix, L Nelles, Bart Smets, L. Lepescheux, Thierry Christophe, Katja Conrath, N. Vandeghinste, Béatrice Vayssière, Steve De Vos, Stephen R. Fletcher, Reginald Brys, Gerben van ‘t Klooster, Jean H.M. Feyen, Christel Menet	181
19	A Novel, Broad-Spectrum Inhibitor of Enterovirus Replication That Targets Host Cell Factor Phosphatidylinositol 4-Kinase IIIβ 2013 ·Antimicrobial Agents and Chemotherapy ·Hilde M. van der Schaar, Pieter Leyssen, Hendrik Jan Thibaut, Armando De Palma, Lonneke van der Linden, Kjerstin Lanke, Céline Lacroix, Erik Verbeken, Katja Conrath, Angus M. MacLeod, (unknown), Nicholas J. Palmer, (unknown), Martin Andrews, Johan Neyts, Frank J. M. van Kuppeveld	98
20	HLA Typing and Lymphocytotoxic Crossmatches using Conventional Techniques or Immunobeads¹ 1991 ·Vox Sanguinis ·G. Mueller‐Eckhardt, (unknown), Katja Conrath, Oskar Hoffmann	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact